Age-related Macular Degeneration (AMD) research hub
5 indexed studies · 4 currently recruiting
- recruitingPHASE3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
This study is looking into new treatments, pozelimab and cemdisiran, for Geographic Atrophy (GA), an advanced form of Age-related Macular Degeneration (AMD). It compares these new drugs, alone or together, against a placebo to see if they can slow down vision loss.
United States · Australia · Austria - enrolling by invitationPHASE2
ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
This study is checking the long-term safety of a treatment called GT005 for an eye condition called Geographic Atrophy, which is linked to Age-related Macular Degeneration (AMD). It’s for people who received GT005 in a previous study.
United States · Australia · France - recruitingPHASE2
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
This study is testing a new eye drop and an injection for a common cause of vision loss called Geographic Atrophy (GA), linked to Age-related Macular Degeneration (AMD). It aims to see how well these treatments work and if they are safe for people aged 55 and over.
United States · Austria · Canada - active not recruiting
Development of Novel Clinical Endpoints in Intermediate AMD
This study looks at how to best measure changes in intermediate Age-related Macular Degeneration (AMD). It aims to find new ways to track the condition's progression, understand how it affects vision, and identify risks for it getting worse. There are no treatments involved.
Denmark · France · Germany - recruiting
Enhanced Vision and Imaging Tests for Enabling Treatment Trials in Early and Intermediate AMD
This study looks at new eye tests for early and intermediate AMD, a common eye condition. We want to see if a test called fundus-tracked dark adaptometry can help doctors measure changes in vision and test new treatments as they develop.
Germany